Dana-Farber Cancer Institute

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research center in Boston, Massachusetts

A breakthrough in the treatment of telomere diseases

A new blood test detected more than 50 types of cancer as well as their location within the body

New tricks for many old drugs to kill cancer cells

A new blood test can detect multiple types of cancer

In study, test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy Test detected methylation patterns associated with cancer in free-floating DNA in blood A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy,

A new blood test can detect multiple types of cancer

Implanting a gel containing immunotherapy during surgical removal of a tumor may prevent the tumor from recurring

A new study by Dana-Farber Cancer Institute scientists suggests it may be possible to prevent tumors from recurring and to eradicate metastatic growths by implanting a gel containing immunotherapy during surgical removal of a tumor. In the study, published online today by Science Translational Medicine, researchers removed breast tumors from mice and placed biodegradable gels

Implanting a gel containing immunotherapy during surgical removal of a tumor may prevent the tumor from recurring

A personal cancer treatment vaccine for melanoma

A personal cancer treatment vaccine that targets distinctive “neoantigens” on tumor cells has been shown to stimulate a potent, safe, and highly specific immune anti-tumor response in melanoma patients, report scientists from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. The study, published online by Nature “provides proof-of-principle that a personal vaccine tailored to a patient’s

A personal cancer treatment vaccine for melanoma

USC scientists open door for asthma cure

Study identifies molecule critical to asthma-causing cell’s survival Scientists led by molecular immunologists at the Keck School of Medicine of the University of Southern California (USC) have identified a way to target a recently discovered cell type that causes asthma, paving the way to cure the chronic respiratory disease that affects 25 million Americans. The

USC scientists open door for asthma cure

Promising results for Swedish cancer drug candidate

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at

Promising results for Swedish cancer drug candidate

Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials

Designed to target skin cancer, the implantable vaccine opens a door to treating many cancers and inflammatory diseases A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer. The effort is the

Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials

Solving Big-Data Bottleneck

Scientists team with business innovators to tackle research hurdles In a study that represents a potential cultural shift in how basic science research can be conducted, researchers from Harvard Medical School, Harvard Business School and London Business School have demonstrated that a crowdsourcing platform pioneered in the commercial sector can solve a complex biological problem

Solving Big-Data Bottleneck

VIDEO: A male contraceptive pill in the making?

“These findings suggest that a reversible, oral male contraceptive may be possible” The development of a male contraceptive pill has long proven to be elusive, but findings from a new study may point scientists in the right direction to making oral birth control for men a reality. Researchers at Dana-Farber Cancer Institute and Baylor College

VIDEO: A male contraceptive pill in the making?

First Targeted Nanomedicine to Enter Human Clinical Studies

BIND-014 is the first targeted and programmed nanomedicine to enter human clinical studies A team of scientists, engineers and physicians from Brigham and Women’s Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell

First Targeted Nanomedicine to Enter Human Clinical Studies

The Latest Bing News on:

Dana-Farber Cancer Institute Research

From Scan to Scan: The Challenges of Living with Metastatic Cancer
Some people with metastatic cancer are living longer than was once possible because of new treatments such as targeted therapies and immunotherapies. NCI recently hosted a conference that brought ...
A dollar sign is hoisted, obscuring the good work of Dana-Farber cancer center
No nonprofit organization, especially a research institute with such a renowned reputation, should have been allowed to adopt a policy by which trustees can use their influence in this way.
Choueiri Shares Highlights From the 2021 Kidney Cancer Research Summit
Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.
New research looks at quality of life impacts from breast cancer surgery
New research is aimed at giving women help to navigate a decision they hope to never face: Choosing a treatment after being diagnosed with breast cancer. It's been almost 10 years since Maggie Loucks, ...
Dana-Farber reverses trustee investment policy
Two longtime Dana-Farber Cancer Institute trustees have resigned, and the Boston-based institute will no longer permit board member investment in hospital startups after a recent Boston Globe ...

The Latest Google Headlines on:

Dana-Farber Cancer Institute Research

A dollar sign is hoisted, obscuring the good work of Dana-Farber cancer center - The Boston Globe
October 15, 2021
Some Dana-Farber Cancer Institute trustees stood to profit from their philanthropic role - The Boston Globe
October 9, 2021
ASH announces Exemplary Service Award recipient - Healio
October 9, 2021
Weighing cancer cells to personalize drug choices | MIT News | Massachusetts Institute of Technology - MIT News
October 5, 2021
Dana-Farber reverses trustee investment policy - Becker's Hospital Review
October 12, 2021

The Latest Bing News on:

Dana-Farber Cancer Institute Discovery

Memorial Sloan Kettering names department chair
Deborah Schrag, MD, MPH, has been appointed chair of the department of medicine at Memorial Sloan Kettering Cancer Center.She succeeds Philip W. Kantoff, MD, who served as department chair for 6 years ...
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
The 8q24 gene desert contains risk loci for multiple epithelial cancers, including colon, breast, and prostate. Recent evidence suggests these risk loci contain enhancers. In this study, data are ...
GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform
GV20 Oncotherapy, a biotechnology company with unique expertise in novel target identification and antibody drug discovery in immuno-oncology, today announced the completion of its Series B financing.
With CEO hire, this Boston biotech boasts an all-woman C-suite
Three months after publicly launching, Kojin Therapeutics has its first CEO in Luba Greenwood — and now boasts an executive team made up entirely of women.
Boston biotech backers quit Dana-Farber board after U-turn on investment policy: report
Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a co-founder of C4 ...